Agios Pharmaceuticals, Inc.
AGIOHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeAgios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. At a $2.21B market cap, Agios Pharmaceuticals, Inc. ranks as a mid-cap company within healthcare. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency.
Market Cap
$2.21B
Beta
0.63
P/E (TTM)
—
P/E (Fwd)
-9.20
EPS (TTM)
$-7.01
EPS (Fwd)
$-4.02
ROE
-34.3%
ROA
-22.2%
Cash
$617.6M
Total Debt
$31.2M
Free CF
-$274.6M
52W Change
-14.1%
Annual Financials
Cash vs Debt
Where AGIO stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, AGIO finished 7.85% above its 150-day moving average ($32.36) and 11.47% above its 200-day moving average ($31.31). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is AGIO overbought or oversold?
At the October 20, 2026 close, AGIO's RSI(14) was 57.2, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $617.6M in cash comfortably exceeding the $31.2M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$274.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -34.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $14.2M (2022) to $54.0M (2025), reflecting a 279% increase over the period.
With a beta below 0.7, Agios Pharmaceuticals, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Agios Pharmaceuticals, Inc. and its sector.